The Times Australia
The Times World News

.

What's available and how to get them

  • Written by Nial Wheate, Associate Professor of the Sydney Pharmacy School, University of Sydney
what's available and how to get them

With COVID case numbers expected to rise[1] in Australia over the coming weeks and months there is significant concern the numbers of severely sick patients may overwhelm hospitals.

Thankfully, over time we are learning more about COVID[2] and now have a range of medicines that are effective in treating it, including antivirals.

Which medicine a patient receives, if they even need one at all, will depend on the severity of their symptoms and whether they have any underlying health problems.

Read more: How are Australia and NZ managing the rising COVID winter wave – and is either getting it right?[3]

Here is what we have in our COVID arsenal

When the COVID pandemic began, we didn’t have any drugs to treat the virus. Instead, we had to rely on drugs that could treat COVID symptoms while the body healed itself.

Now we have a range of recommended COVID medicines[4] that are either antivirals or antibody-based drugs. These are suitable for both hospitalised and at-home patients and include lagevrio[5], remdesivir[6], paxlovid[7], evusheld[8] and sotrovimab[9].

In Australia, there are other antibody drugs available but they are not currently widely used. This includes ronapreve[10], which is less effective[11] against the omicron strain of the virus, and regkirona[12] which is still being explored in clinical trials[13].

Other drugs are also used for COVID but, again, they don’t treat the virus. Instead they are mostly used to reduce inflammation in the lungs.

These medicines have all been shown to work in human clinical trials and are either fully or provisionally approved by the Australian Therapeutic Goods Administration[14] for the treatment of COVID.

Each COVID medicine works in a different way. Evusheld and sotrovimab comprise antibody molecules that neutralise the virus and block its entry into human cells, whereas paxlovid works by stopping a key enzyme the virus needs to replicate. Both lagevrio and remdesivir work by getting incorporated into the virus’ genetic material and causing mutations to stop the virus from replicating.

Paxlovid and lagevrio come in tablet form while remdesivir, sotrovimab, and evusheld come as injections that need to be administered by a doctor.

older man sick in bed with tissue
Who you are and whether you are at home or in hospital will determine your treatment. Shutterstock[15]

Read more: Australia approves two new medicines in the fight against COVID. How can you get them and are they effective against Omicron?[16]

The right drug for the right patient

Clinical guidelines[17] direct health staff as to which drug they need to administer to each patient.

Most people who test positive for COVID will not need treatment with an antiviral drug, as current COVID variants tend to induce mild symptoms that can be managed with rest and isolation at home.

For some patients managing COVID at home, certain health factors mean their doctor will prescribe a COVID drug. This includes people who have a poor functioning immune system, those who are not vaccinated or are not up-to-date with vaccinations, and those who are at a high risk of severe disease.

These risk factors[18] include respiratory conditions such as asthma, cardiovascular diseases including high blood pressure, obesity, diabetes and kidney failure.

Where you’re treated

If a patient is sick enough to need hospitalisation, specialist doctors will decide if and what COVID drug to prescribe.

If a COVID drug is needed for an at-home patient both lagevrio and paxlovid are available on the Pharmaceutical Benefits Scheme (PBS)[19] for specific people[20] including those over 70, or those over 50 who have one of the risk factors mentioned earlier.

Immunocompromised people over the age of 18, and people who identify as Aboriginal or Torres Strait Islander origin who are over 30 and at high risk, are also eligible for PBS-subsidised lagevrio or paxlovid.

These drugs can be prescribed by a general practitioner (GP) and accessed through a local community pharmacy. If a patient is not able to see their GP in person, a COVID drug can be prescribed by booking a telehealth appointment[21] with a doctor. The drug can then be delivered to their home from their local pharmacy. Importantly, these drugs must be started within five days of symptom onset[22].

In some instances an at-home COVID patient may require an injection-only drug such as remdesivir or evusheld, which are only available through the patient’s local hospital network. Sotrovimab is another COVID drug that is only administered in healthcare facilities. This is because patients need to be monitored after they receive the infusion. General practitioners will refer their patients to a local hospital for these treatments.

Read more: I have mild COVID – should I take the antiviral Paxlovid?[23]

What about side effects?

All medicines have side effects, even common medications like paracetamol and aspirin.

If patients do experience side effects, these are likely to be specific to the drug being taken. Some of the possible side effects of lagevrio[24] include mild to moderate diarrhoea, nausea and dizziness in less than 2% of those trialled.

For paxlovid[25], side effects can include changes in taste, diarrhoea, headache, and vomiting. Serious side effects, which affect fewer than 2% of patients[26], include liver problems which can cause prolonged nausea or vomiting, loss of appetite, stomach pain, yellowing eyes or skin, and dark urine[27].

Some of the side effects of remdesivir[28] include rash, sweating, fever, shortness of breath, swelling, changes in blood pressure or heart rate, nausea, and shivering.

Patients who experience side effects while taking a COVID drug should see their doctor if they are concerned. If a patient experiences any severe side effects, such as signs of liver problems, then they should call their doctor immediately or go straight to their local hospital.

References

  1. ^ COVID case numbers expected to rise (www.abc.net.au)
  2. ^ we are learning more about COVID (theconversation.com)
  3. ^ How are Australia and NZ managing the rising COVID winter wave – and is either getting it right? (theconversation.com)
  4. ^ recommended COVID medicines (www.health.gov.au)
  5. ^ lagevrio (www.nps.org.au)
  6. ^ remdesivir (www.nps.org.au)
  7. ^ paxlovid (www.tga.gov.au)
  8. ^ evusheld (www.health.gov.au)
  9. ^ sotrovimab (www.fda.gov)
  10. ^ ronapreve (www.tga.gov.au)
  11. ^ less effective (covid19evidence.net.au)
  12. ^ regkirona (www.tga.gov.au)
  13. ^ clinical trials (app.magicapp.org)
  14. ^ Therapeutic Goods Administration (tga.gov.au)
  15. ^ Shutterstock (image.shutterstock.com)
  16. ^ Australia approves two new medicines in the fight against COVID. How can you get them and are they effective against Omicron? (theconversation.com)
  17. ^ Clinical guidelines (covid19evidence.net.au)
  18. ^ risk factors (www.health.gov.au)
  19. ^ lagevrio and paxlovid are available on the Pharmaceutical Benefits Scheme (PBS) (www.health.gov.au)
  20. ^ specific people (www.pbs.gov.au)
  21. ^ telehealth appointment (www.health.gov.au)
  22. ^ five days of symptom onset (www.tga.gov.au)
  23. ^ I have mild COVID – should I take the antiviral Paxlovid? (theconversation.com)
  24. ^ lagevrio (www.nps.org.au)
  25. ^ paxlovid (www.nps.org.au)
  26. ^ fewer than 2% of patients (www.tga.gov.au)
  27. ^ dark urine (www.webmd.com)
  28. ^ side effects of remdesivir (www.ebs.tga.gov.au)

Read more https://theconversation.com/covid-drugs-in-australia-whats-available-and-how-to-get-them-186907

Times Magazine

Headless CMS in Digital Twins and 3D Product Experiences

Image by freepik As the metaverse becomes more advanced and accessible, it's clear that multiple sectors will use digital twins and 3D product experiences to visualize, connect, and streamline efforts better. A digital twin is a virtual replica of ...

The Decline of Hyper-Casual: How Mid-Core Mobile Games Took Over in 2025

In recent years, the mobile gaming landscape has undergone a significant transformation, with mid-core mobile games emerging as the dominant force in app stores by 2025. This shift is underpinned by changing user habits and evolving monetization tr...

Understanding ITIL 4 and PRINCE2 Project Management Synergy

Key Highlights ITIL 4 focuses on IT service management, emphasising continual improvement and value creation through modern digital transformation approaches. PRINCE2 project management supports systematic planning and execution of projects wit...

What AI Adoption Means for the Future of Workplace Risk Management

Image by freepik As industrial operations become more complex and fast-paced, the risks faced by workers and employers alike continue to grow. Traditional safety models—reliant on manual oversight, reactive investigations, and standardised checklist...

From Beach Bops to Alpine Anthems: Your Sonos Survival Guide for a Long Weekend Escape

Alright, fellow adventurers and relaxation enthusiasts! So, you've packed your bags, charged your devices, and mentally prepared for that glorious King's Birthday long weekend. But hold on, are you really ready? Because a true long weekend warrior kn...

Effective Commercial Pest Control Solutions for a Safer Workplace

Keeping a workplace clean, safe, and free from pests is essential for maintaining productivity, protecting employee health, and upholding a company's reputation. Pests pose health risks, can cause structural damage, and can lead to serious legal an...

The Times Features

Tricia Paoluccio designer to the stars

The Case for Nuturing Creativity in the Classroom, and in our Lives I am an actress and an artist who has had the privilege of sharing my work across many countries, touring my ...

Duke of Dural to Get Rooftop Bar as New Owners Invest in Venue Upgrade

The Duke of Dural, in Sydney’s north-west, is set for a major uplift under new ownership, following its acquisition by hospitality group Good Beer Company this week. Led by resp...

Prefab’s Second Life: Why Australia’s Backyard Boom Needs a Circular Makeover

The humble granny flat is being reimagined not just as a fix for housing shortages, but as a cornerstone of circular, factory-built architecture. But are our systems ready to s...

Melbourne’s Burglary Boom: Break-Ins Surge Nearly 25%

Victorian homeowners are being warned to act now, as rising break-ins and falling arrest rates paint a worrying picture for suburban safety. Melbourne residents are facing an ...

Exploring the Curriculum at a Modern Junior School in Melbourne

Key Highlights The curriculum at junior schools emphasises whole-person development, catering to children’s physical, emotional, and intellectual needs. It ensures early year...

Distressed by all the bad news? Here’s how to stay informed but still look after yourself

If you’re feeling like the news is particularly bad at the moment, you’re not alone. But many of us can’t look away – and don’t want to. Engaging with news can help us make ...